Revisiting Peripartum Cardiomyopathy: A Case Report and Review
Main Article Content
Abstract
Peripartum cardiomyopathy (PPCM) is a rare and idiopathic disease characterized by left ventricular dilation and systolic dysfunction, that occurs late in pregnancy or during the postpartum period. Diagnosis is typically achieved through transthoracic echocardiography and cardiac magnetic resonance imaging (MRI). Management includes standard heart failure therapies such as beta-blockers, ACE inhibitors, and diuretics, with the addition of bromocriptine to target the prolactin pathway involved in PPCM pathophysiology. This report presents a case of a 31-year-old female with a history of acute lymphoblastic leukemia who, following an uncomplicated pregnancy, presented with acute heart failure symptoms. Initial evaluations suggested pulmonary embolism, but further diagnostic workup, including echocardiography and cardiac MRI, confirmed PPCM. The patient was treated with diuretics, ACE inhibitors, and beta blockers. Significant improvement was observed, with complete resolution and normal cardiac function at the 6-month follow-up.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283(9):1183-1188. doi:10.1001/jama.283.9.1183
II. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(2):207-221. doi:10.1016/j.jacc.2019.11.014
III. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364:k5287. Published 2019 Jan 30. doi:10.1136/bmj.k5287
IV. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014;3(3):e001056. Published 2014 Jun 4. doi:10.1161/JAHA.114.001056
V. Kao DP, Hsich E, Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail. 2013;1(5):409-416. doi:10.1016/j.jchf.2013.04.011
VI. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589-600. doi:10.1016/j.cell.2006.12.036
VII. Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016;133(14):1397-1409. doi:10.1161/CIRCULATIONAHA.115.020491
VIII. Ricci F, De Innocentiis C, Verrengia E, et al. The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy. Front Cardiovasc Med. 2020;7:4. Published 2020 Feb 18. doi:10.3389/fcvm.2020.00004
IX. Jha N, Jha AK. Peripartum cardiomyopathy. Heart Fail Rev. 2021;26(4):781-797. doi:10.1007/s10741-020-10060-y
X. Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: from genetics to management. Eur Heart J. 2021;42(32):3094-3102. doi:10.1093/eurheartj/ehab458
XI. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi:10.1093/eurheartj/ehad194